No serious concerns about Eli Lilly's Alzheimer's drugs = US FDA

No serious concerns about Eli Lilly's Alzheimer's drugs = US FDA(some excerpts)

The U.S. Food and Drug Administration (FDA) announced on the 6th that US pharmaceutical giant Eli Lilly(LY.N)It was announced that no serious risk was observed in the analysis of clinical trial data for the early Alzheimer's disease treatment drug “donanemab,” which is being developed. It also raised questions about safety for early Alzheimer's patients.

If the same drug is approved, Eisai(4523.T)and rice biogen(BIIB.O)It competes with “Rekenbi,” which was jointly developed by The rekenbi was approved in July last year.